Lars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses the use of lenvatinib to treat patients with non-small cell lung cancer (NSCLC) at the 2016 ESMO Congress.

A phase II study of the agent demonstrated promising clinical activity in a small subset of patients with NSCLC. Approximately 40% of these patients have adenocarcinoma of the lung, and 1% to 2% of those patients have a 

 mutation. It is in this specific setting, Bastholt explains, that lenvatinib has demonstrated significant outcomes.

Despite some manageable toxicities associated with this agent, these efficacious results provide support for further study of lenvatinib for 

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Lung Cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

ESMO Congress

Lars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses the use of lenvatinib to treat patients with non-small cell lung cancer at the 2016 ESMO Congress.

Dr. Bastholt on Lenvatinib in NSCLC